In setting diagnostic goals, scientists have found a number of PARP-1 inhibitors, that can be used in many anti-cancer therapies, and are already applied in the treatment of gynecological cancers, such as endometrial, breast and ovarian cancer [18,19,20]. This evidence concerns the gene PARP1 and ovarian cancer.